Abbott Laboratories (NYSE:ABT) announced that it has received the fifth indication for its drug Humira. The new indication gives the company U.S. Food and Drug Administration approval to market Humira as a treatment for moderate to severe psoriasis.
"The approval of HUMIRA for psoriasis is welcome news for people living with this challenging, lifelong disease," said Pam Field, acting president and CEO, National Psoriasis Foundation. "We are pleased to let people with plaque psoriasis know they now have a new treatment option available to them."
Psoriasis is an autoimmune disease that is characterized by skin lesions that can be painful and itchy. It is estimated that 125 million people worldwide suffer from psoriasis which can lead to poor self-image and isolation to due the inflamed lesions that can crack or bleed.
Approval was based on two trials which demonstrated the Humira significantly reduced the signs and symptoms of the psoriasis when compared to results of those patients that had been placed on a placebo.
"HUMIRA has demonstrated its versatility in effectively treating multiple autoimmune diseases, and this approval expands the therapeutic resources available to dermatologists and other physicians who take care of patients with psoriasis and psoriatic arthritis," said Eugene Sun, M.D., vice president, Global Pharmaceutical Clinical Development, Abbott.
[Source: PRNewsWire]
.jpg)
» Related News Stories from Connecting News, Commentaries and Blogs at NineReports.com
Abbott expands nutritionals, Kaletra AIDS drug for kids ...Blogged about at Abbott Gets FDA Approval for Humira for Plaque Psoriasis - pharmagazette, Moving to capitalize on increased demand for nutritional products in the booming economies of southea... [Read More]
Tracked on: January 30, 2008 2:46 PM | Permalink to Trackback